BIIB
VENTE TOTALE: 1 186 titres (~239 749,90 $ US)
- Insiders
- Minor Lloyd
- Total bought
- —
- Total sold
- $239,750
- Last activity
- 2026-08-04
- Last synced
-
2026-08-10 09:45:27
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bullish signal Scored 2026-09-06
BIIB presents a compelling near-term event-driven opportunity driven by a strong Q2 2026 earnings beat, raised guidance, and the RayThera acquisition adding pipeline momentum, supported by solid liquidity (score: 85).
The first sentence of the analysis written for BIIB on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 70.5% | 76.1% | 74.2% | 77.6% | 80.8% | |
| Ebit Margin | 22.1% | 24.0% | 19.1% | 29.7% | 31.3% | |
| Ebitda Margin | 31.6% | 31.0% | 24.2% | 34.8% | 35.7% | |
| Operating Profit Margin | 19.1% | 25.7% | 21.3% | 28.4% | 25.4% | |
| Pretax Profit Margin | 14.3% | 19.7% | 13.2% | 35.3% | 16.2% | |
| Continuous Operations Profit Margin | 13.2% | 16.9% | 11.8% | 29.1% | 15.7% | |
| Net Profit Margin | 13.2% | 16.9% | 11.8% | 29.9% | 14.2% | |
| Bottom Line Profit Margin | 13.2% | 16.9% | 11.8% | 29.9% | 14.2% | |
| Current Ratio | 2.679 | 1.349 | 1.997 | 2.992 | 1.828 | |
| Quick Ratio | 2.032 | 0.904 | 1.261 | 2.581 | 1.513 | |
| Solvency Ratio | 0.199 | 0.203 | 0.137 | 0.319 | 0.158 | |
| Cash Ratio | 0.898 | 0.430 | 0.306 | 1.045 | 0.526 | |
| Price To Earnings Ratio | 19.886 | 13.654 | 32.266 | 13.206 | 22.981 | |
| Price To Earnings Growth Ratio | -0.948 | 0.344 | -0.522 | 0.131 | -0.396 | |
| Forward Price To Earnings Growth Ratio | -0.948 | 0.344 | -0.522 | 0.131 | -0.396 | |
| Price To Earnings Diluted Ratio | 19.931 | 13.666 | 32.468 | 13.269 | 23.069 | |
| Price To Earnings Diluted Growth Ratio | -0.945 | 0.338 | -0.525 | 0.132 | -0.397 | |
| Price To Book Ratio | 1.414 | 1.333 | 2.530 | 3.003 | 3.283 | |
| Price To Sales Ratio | 2.632 | 2.303 | 3.807 | 3.955 | 3.257 | |
| Price To Free Cash Flow Ratio | 12.589 | 8.857 | 30.299 | 35.172 | 10.578 | |
| Price To Operating Cash Flow Ratio | 11.711 | 7.748 | 24.201 | 29.066 | 9.828 | |
| Debt To Assets Ratio | 0.236 | 0.236 | 0.273 | 0.269 | 0.318 | |
| Debt To Equity Ratio | 0.381 | 0.397 | 0.496 | 0.494 | 0.698 | |
| Debt To Capital Ratio | 0.276 | 0.284 | 0.331 | 0.331 | 0.411 | |
| Long Term Debt To Capital Ratio | 0.265 | 0.214 | 0.314 | 0.319 | 0.365 | |
| Financial Leverage Ratio | 1.613 | 1.678 | 1.814 | 1.833 | 2.191 | |
| Working Capital Turnover Ratio | 2.598 | 3.615 | 1.978 | 2.019 | 3.277 | |
| Operating Cash Flow Ratio | 0.658 | 0.520 | 0.451 | 0.423 | 0.847 | |
| Operating Cash Flow Sales Ratio | 0.225 | 0.297 | 0.157 | 0.136 | 0.331 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.930 | 0.875 | 0.799 | 0.826 | 0.929 | |
| Debt Service Coverage Ratio | 9.168 | 1.362 | 5.648 | 11.777 | 3.090 | |
| Interest Coverage Ratio | 7.632 | 9.949 | 8.495 | 11.716 | 11.007 | |
| Short Term Operating Cash Flow Coverage Ratio | 27.420 | 1.644 | 10.315 | 0.000 | 3.643 | |
| Operating Cash Flow Coverage Ratio | 0.317 | 0.434 | 0.211 | 0.209 | 0.479 | |
| Capital Expenditure Coverage Ratio | 14.334 | 7.992 | 4.969 | 5.761 | 14.103 | |
| Dividend Paid And Capex Coverage Ratio | 14.334 | 7.992 | 4.969 | 5.761 | 14.103 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 9.597 | 8.858 | 18.398 | 12.279 | 10.479 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 70.5% | ▼-5.7% | ▼-5.4% |
| Ebit Margin | 22.1% | ▼-1.9% | ▼-3.2% |
| Ebitda Margin | 31.6% | ▲0.6% | ▲0.2% |
| Operating Profit Margin | 19.1% | ▼-6.6% | ▼-4.9% |
| Pretax Profit Margin | 14.3% | ▼-5.4% | ▼-5.5% |
| Continuous Operations Profit Margin | 13.2% | ▼-3.7% | ▼-4.2% |
| Net Profit Margin | 13.2% | ▼-3.7% | ▼-4.0% |
| Bottom Line Profit Margin | 13.2% | ▼-3.7% | ▼-4.0% |
| Current Ratio | 2.679 | ▲1.331 | ▲0.510 |
| Quick Ratio | 2.032 | ▲1.128 | ▲0.374 |
| Solvency Ratio | 0.199 | ▼-0.004 | ▼-0.004 |
| Cash Ratio | 0.898 | ▲0.469 | ▲0.257 |
| Price To Earnings Ratio | 19.886 | ▲6.232 | ▼-0.512 |
| Price To Earnings Growth Ratio | -0.948 | ▼-1.292 | ▼-0.669 |
| Forward Price To Earnings Growth Ratio | -0.948 | ▼-1.292 | ▼-0.669 |
| Price To Earnings Diluted Ratio | 19.931 | ▲6.265 | ▼-0.550 |
| Price To Earnings Diluted Growth Ratio | -0.945 | ▼-1.283 | ▼-0.665 |
| Price To Book Ratio | 1.414 | ▲0.081 | ▼-0.898 |
| Price To Sales Ratio | 2.632 | ▲0.329 | ▼-0.559 |
| Price To Free Cash Flow Ratio | 12.589 | ▲3.732 | ▼-6.910 |
| Price To Operating Cash Flow Ratio | 11.711 | ▲3.962 | ▼-4.800 |
| Debt To Assets Ratio | 0.236 | ▼-0.000 | ▼-0.031 |
| Debt To Equity Ratio | 0.381 | ▼-0.016 | ▼-0.112 |
| Debt To Capital Ratio | 0.276 | ▼-0.008 | ▼-0.051 |
| Long Term Debt To Capital Ratio | 0.265 | ▲0.051 | ▼-0.031 |
| Financial Leverage Ratio | 1.613 | ▼-0.066 | ▼-0.213 |
| Working Capital Turnover Ratio | 2.598 | ▼-1.017 | ▼-0.100 |
| Operating Cash Flow Ratio | 0.658 | ▲0.138 | ▲0.079 |
| Operating Cash Flow Sales Ratio | 0.225 | ▼-0.072 | ▼-0.005 |
| Free Cash Flow Operating Cash Flow Ratio | 0.930 | ▲0.055 | ▲0.058 |
| Debt Service Coverage Ratio | 9.168 | ▲7.806 | ▲2.959 |
| Interest Coverage Ratio | 7.632 | ▼-2.317 | ▼-2.128 |
| Short Term Operating Cash Flow Coverage Ratio | 27.420 | ▲25.776 | ▲18.816 |
| Operating Cash Flow Coverage Ratio | 0.317 | ▼-0.116 | ▼-0.013 |
| Capital Expenditure Coverage Ratio | 14.334 | ▲6.342 | ▲4.903 |
| Dividend Paid And Capex Coverage Ratio | 14.334 | ▲6.342 | ▲4.903 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 9.597 | ▲0.739 | ▼-2.325 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $25.82B | $22.28B | $37.44B | $40.24B | $35.77B | |
| Enterprise value | $29.76B | $26.54B | $43.73B | $43.43B | $41.11B | |
| EV / Sales | 3.03x | 2.74x | 4.45x | 4.27x | 3.74x | |
| EV / Op. cash flow | 13.50x | 9.23x | 28.27x | 31.37x | 11.29x | |
| EV / Free cash flow | 14.51x | 10.55x | 35.39x | 37.96x | 12.16x | |
| EV / EBITDA | 9.60x | 8.86x | 18.40x | 12.28x | 10.48x | |
| Net debt / EBITDA | 1.27x | 1.42x | 2.65x | 0.90x | 1.36x | |
| Current ratio | 2.68x | 1.35x | 2.00x | 2.99x | 1.83x | |
| Income quality | 1.71x | 1.76x | 1.33x | 0.47x | 2.11x | |
| Graham number | $157 | $170 | $136 | $209 | $131 | |
| Graham net-net | -$33 | -$43 | -$56 | -$28 | -$47 | |
| Tax burden | 92.3% | 85.6% | 89.5% | 84.8% | 87.4% | |
| Interest burden | 64.7% | 82.1% | 68.9% | 119.1% | 51.8% | |
| Working capital | $5.62B | $1.93B | $3.42B | $6.52B | $3.56B | |
| Invested capital | $24.62B | $21.64B | $21.74B | $17.82B | $15.33B | |
| Return on assets | 4.4% | 5.8% | 4.3% | 12.4% | 6.5% | |
| Operating ROA | 6.5% | 9.1% | 8.2% | 11.9% | 11.5% | |
| Return on tangible assets | 9.4% | 13.7% | 9.5% | 18.0% | 9.8% | |
| Return on equity | 7.1% | 9.8% | 7.8% | 22.7% | 14.3% | |
| Return on invested capital | 6.6% | 8.8% | 8.0% | 11.2% | 13.2% | |
| Return on capital employed | 7.2% | 11.1% | 9.0% | 13.6% | 14.3% | |
| Earnings yield | 5.0% | 7.3% | 3.1% | 7.6% | 4.4% | |
| Free cash flow yield | 7.9% | 11.3% | 3.3% | 2.8% | 9.5% | |
| Capex / Op. cash flow | 7.0% | 12.5% | 20.1% | 17.4% | 7.1% | |
| Capex / Depreciation | 19.7% | 53.4% | 62.9% | 46.4% | 52.9% | |
| Capex / Sales | 1.6% | 3.7% | 3.2% | 2.4% | 2.4% | |
| SG&A / Sales | 24.8% | 24.7% | 25.4% | 23.7% | 24.4% | |
| R&D / Sales | 19.9% | 25.7% | 27.5% | 25.5% | 31.0% | |
| Stock comp / Sales | 3.0% | 3.0% | 2.7% | 2.5% | 2.2% | |
| Intangibles / Total assets | 53.2% | 57.6% | 54.3% | 30.9% | 33.4% | |
| Days sales outstanding | 69d | 70d | 78d | 77d | 65d | |
| Days payables outstanding | 54d | 67d | 58d | 79d | 102d | |
| Operating cycle | 343d | 459d | 442d | 292d | 299d | |
| Cash conversion cycle | 288d | 392d | 384d | 213d | 197d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+15.9%EV / Sales ▲+10.6%EV / EBITDA ▲+8.3%EV / Op. cash flow ▲+4.270Earnings yield ▼-0.023Graham number ▼-12.931
Profitability
Return on equity ▼-0.027Return on assets ▼-0.014Return on invested capital ▼-0.022Return on capital employed ▼-0.039Operating ROA ▼-0.025Income quality ▼-0.057Tax burden ▲+0.067
Efficiency
Days sales outstanding ▼-1.035Days payables outstanding ▼-12.587Operating cycle ▼-116.584Cash conversion cycle ▼-103.997Capex / Sales ▼-0.022R&D / Sales ▼-0.058
Balance-sheet strength
Current ratio ▲+1.331Net debt / EBITDA ▼-0.150Working capital ▲+3696700000.000Invested capital ▲+2979300000.000Intangibles / Total assets ▼-0.044
Change over 5 years
Valuation
Market cap ▼-27.8%EV / Sales ▼-19.0%EV / EBITDA ▼-8.4%EV / Op. cash flow ▲+2.202Earnings yield ▲+0.007Graham number ▲+26.123
Profitability
Return on equity ▼-0.072Return on assets ▼-0.021Return on invested capital ▼-0.065Return on capital employed ▼-0.071Operating ROA ▼-0.050Income quality ▼-0.402Tax burden ▲+0.049
Efficiency
Days sales outstanding ▲+4.260Days payables outstanding ▼-47.509Operating cycle ▲+43.600Cash conversion cycle ▲+91.109Capex / Sales ▼-0.008R&D / Sales ▼-0.110
Balance-sheet strength
Current ratio ▲+0.851Net debt / EBITDA ▼-0.091Working capital ▲+2066400000.000Invested capital ▲+9282600000.000Intangibles / Total assets ▲+0.198
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-06-05 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-06-02 | Maria Elvira Salazar | Sale | $15,001 - $50,000 |
| 2026-05-12 | Maria Elvira Salazar | Purchase | $1,001 - $15,000 |
| 2026-05-11 | Maria Elvira Salazar | Purchase | $1,001 - $15,000 |
| 2026-05-11 | Maria Elvira Salazar | Purchase | $50,001 - $100,000 |
| 2026-01-30 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-08-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-05-15 | Rob Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-04-08 | Rob Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-02-25 | Rob Bresnahan | Purchase | $1,001 - $15,000 |
| 2024-11-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-03-25 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-03-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-04-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Sale (Partial) | $1,001 - $15,000 |
| 2023-02-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-03 | Kathy Manning | Sale (Full) | $1,001 - $15,000 |
| 2022-08-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-07-20 | Kathy Manning | Purchase | $1,001 - $15,000 |
| 2022-06-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-04-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-03-17 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-20 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-14 | Kathy Manning | Sale (Full) | $1,001 - $15,000 |
| 2022-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-10 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2021-12-09 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2021-10-18 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2021-09-15 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2021-06-08 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2021-02-16 | Peter Meijer | Sale (Full) | $15,001 - $50,000 |
| 2021-01-04 | Chris Jacobs | Sale (Full) | $1,001 - $15,000 |
| 2020-12-22 | Gilbert Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2020-09-16 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-07-07 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2020-04-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-03-18 | Gilbert Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2020-02-07 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2019-06-24 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
| 2019-06-20 | Dean Phillips | Purchase | $1,001 - $15,000 |
| 2018-10-29 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2018-10-05 | Gary Palmer | Sale (Full) | $1,001 - $15,000 |
Recent news
- 2026-08-06 Biogen Completes Acquisition of RayThera Inc. CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology.
- 2026-08-01 Biogen Inc. $BIIB Shares Acquired by Amundi Amundi increased its stake in Biogen Inc. (NASDAQ: BIIB) by 38.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 790,827 shares of the biotechnology company''s stock after buying an additional 218,398 shares during the period. Amundi owned about 0.54%
- 2026-07-29 Why Biogen Stock Topped the Market Today It handily beat analyst estimates on both the top and bottom lines. Investors didn''t even mind a cut in adjusted net income guidance.
- 2026-07-29 Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript
- 2026-07-29 Biogen Boosts Profit Forecast with Growth Across Alzheimer''s, Rare Disease Portfolio Biogen Inc. (NASDAQ:BIIB) stock is trading higher on Wednesday after the company reported second-quarter adjusted earnings of $3.60 per share, beating the consensus of $2.96.
- 2026-07-29 Q2 Earnings Season in Full Swing Pre-market futures are flat-to-down ahead of today''s open, with overseas turbulence in the memory chip market reverberating on domestic shores. We also see something of a hesitation in trading ahead of this afternoon''s Fed decision on interest rates.
- 2026-07-29 Biogen''s Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.
- 2026-07-29 Investors Await Fed Decision Today A quarter-points rate hike has been bandied about as a possibility today.
- 2026-07-29 Biogen: The Turnaround Is Real Enough To Buy (Rating Upgrade) Biogen Inc. is upgraded to ''Buy'' as strategic acquisitions and pipeline progress offset multiple sclerosis portfolio erosion. Q2 revenue grew 3% Y/Y, aided by Apellis acquisition, rare disease, and Alzheimer''s collaboration, with LEQEMBI gaining global traction. Felzartamab''s multi-indication potential and upcoming pivotal trial readouts underpin BIIB''s long-term growth prospects.
- 2026-07-29 Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.